A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
NCT07194850 · Advance Jr Phase 2/3Recruiting
- Lead sponsor
- argenx (Industry)
- Enrollment
- 24 (estimated)
- Start date
- 20 Oct 2025
- Primary completion
- Oct 2028 (estimated)
- Study completion
- 1 Oct 2030
- Last update posted
- 16 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Quadruple
- Arms
- 2
Interventions
- Efgartigimod IV Biological
- Placebo IV Other
Conditions and primary outcome
- Immune Thrombocytopenia (ITP)
- ITP - Immune Thrombocytopenia
- ITP
- Immune Thrombocytopenic Purpura
- Immune Thrombocytopenic Purpura ( ITP )
- Idiopathic Thrombocytopenic Purpura
- Idiopathic Thrombocytopenic Purpura (ITP)
Primary outcome
Efgartigimod serum concentrations in the DBTP (Up to 24 weeks); Total IgG levels in the DBTP (Up to 24 weeks)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT07194850.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT07194850 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.